Treatment of Alopecia Areata with Tofacitinib – A Jak Inhibitor
DOI:
https://doi.org/10.21276/9yvhvs14Keywords:
alopecia areata, tofacitinib, JAK inhibitorsAbstract
Alopecia areata is an autoimmune non-scarring hair loss with a lifetime prevalence of 2% characterized by patches of hair loss in normal hair bearing areas. Key pathogenic events involves attack on hair follicles by auto-reactive CD8- T cells and local secretion of interferon (IFN)-gamma and interleukin (IL)-15 which activate target immune cells via the janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling pathway.
We describe 10 patients to evaluate the efficacy of oral tofacitinib, a janus- kinase 1 and 3 inhibitor in the treatment of alopecia areata.
A prospective study was conducted wherein the participants were given tablet tofacitinib 5 mg twice a day for 6 months and followed up for next 6 months after completion of treatment.
The minimum and maximum SALT scores were 26 and 96 respectively , with the mean SALT score of 45. 4 out of 10 patients achieved a SALT score of 0 by the end of therapy , all with either patchy or alopecia totalis pattern of hair-loss. Participants responded markedly in the first 3 months of therapy with complete regrowth in 6 months.
Pathogenesis of alopecia areata is not yet clearly defined however, JAK inhibitors seem to show promising results. The aim of our study is to highlight that if used within 6 months and in certain types of alopecia areata there can be great results with JAK inhibitors, however the major drawback is relapse of disease after stopping the treatment.
Downloads
References
Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of
alopecia areata in Olmsted county, Minnesota, 1975 through 1989. MayoClin
Proc 1995; 70:628‑33
Gilhar A, Schrum AG, Etzioni A, Waldmann H, Paus R. Alopecia areata: Animal
models illuminate autoimmune pathogenesis and novel immunotherapeutic
strategies. Autoimmun Rev. 2016; 15(7):726–735.
Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: New
approaches, new findings, new treatments. J Dermatol Sci 2015; 78:11‑20.
Alopecia areata: a review of disease pathogenesis. Rajabi F, Drake LA, Senna
MM, Rezaei N Br J Dermatol. 2018;179(5):1033.
Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J
Investig Dermatol Symp Proc. 2003;8(2):188–194.
Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T
lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–
Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle immune privilege is
linked to prevention of NK cell attack. J Invest Dermatol. 2008;128(5):1196–
Gilhar A, Schrum AG, Etzioni A, Waldmann H, Paus R. Alopecia areata: Animal
models illuminate autoimmune pathogenesis and novel immunotherapeutic
strategies. Autoimmun Rev. 2016; 15(7):726–735. [PubMed: 26971464]
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe
alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol
;76:22e8.
Bansal A, Relhan V, et al. A cross-sectional study of the histopathology and
immunology of alopecia areata: Unearthing the role of the Janus kinase–signal
transducer and activator of transcription pathway. IJDVL 2019;85(5):455-461
-Xiu Dai, Chih-Chiang Chen. Tofacitinib therapy for children with severe
alopecia areata. JAAD 2019; 80(4):1164-1166.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Archives of BioMedical and Clinical Research (IABCR)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
